๐
Lumoxiti
moxetumomab pasudotox
Leukemia, Hairy Cell
๐ซ Withdrawn
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/lumoxiti